Skip to main content

Table 2 Univariate and multivariate Cox regressions for candidate biomarkers in mantle cell lymphoma survival

From: Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma

Biomarker

Univariate

Multivariate

EFS

HR (95% CI)

p

OS

HR (95% CI)

p

EFS*

HR (95% CI)

p

OS*

HR (95% CI)

p

Immunohistochemical model

 FOXP3/CD3 ratio

  High

3.16 (1.52–6.58)

0.002

1.77 (0.75–4.19)

0.18

5.03 (1.97–12.84)

0.001a

N/A

N/A

  Low

Reference

 

Reference

 

Reference

 

Reference

 

 CD8/CD3 ratio

  High

2.22 (1.04–4.77)

0.03

1.06 (0.44–2.51)

0.88

1.02 (0.33–3.13)

0.96

N/A

N/A

  Low

Reference

 

Reference

 

Reference

 

Reference

 

 Granzyme B

  High

0.50 (0.24–1.04)

0.06

0.69 (0.28–1.67)

0.41

1.18 (0.51–2.72)

0.69

N/A

N/A

  Low

Reference

 

Reference

 

Reference

 

Reference

 

 IL2

  High

Reference

0.01

Reference

 

Reference

0.03b

Reference

0.07

  Low

2.71 (1.26–5.83)

2.06 (0.88–4.80)

0.09

2.83 (1.06–7.58)

2.50 (0.92–6.77)

 IL17A

  High

1.48 (0.73–2.97)

0.27

2.55 (1.06–6.12)

0.03

N/A

N/A

4.68 (1.72–12.77)

0.003c

  Low

Reference

 

Reference

 

Reference

 

Reference

 

SNV model

 IL2 rs2069762

  GG

4.26 (1.56–11.60)

0.005

9.05 (2.33–35.05)

0.001

3.13 (1.12–8.69)

0.02d

2.73 (0.86–8.67)

0.08

  GT+TT

Reference

 

Reference

 

Reference

 

Reference

 

 TGFB1 rs6957

  GG

1.86 (0.43–7.92)

0.39

5.38 (1.17–24.73)

0.03

N/A

N/A

3.22 (0.57–18.15)

0.18

  GA + AA

Reference

 

Reference

 

Reference

 

Reference

 

 TGFBR2 rs3087465

  AA+AG

3.40 (1.60–7.22)

0.001

1.37 (0.56–3.36)

0.47

4.32 (1.88–9.93)

0.001e

N/A

N/A

  GG

Reference

 

Reference

 

Reference

 

Reference

 

 IL10 CC haplotype

  Present

0.45 (0.21–0.97)

0.04

0.28 (0.11–0.70)

0.007

0.32 (0.14–0.74)

0.008f

0.26 (0.10–0.68)

0.006g

  Absent

Reference

 

Reference

 

Reference

 

Reference

 

 IL17F rs763780

  TC + CC

0.40 (0.17–0.91)

0.03

1.16 (0.34–3.99)

0.80

1.42 (0.47–4.23)

0.52

N/A

N/A

  TT

Reference

 

Reference

 

Reference

 

Reference

 

Principal components model

 Component 3

0.670 (0.40–1.10)

0.12

0.58 (0.31–1.08)

0.08

N/A

N/A

0.77 (0.48–1.24)

0.29

 Component 4

1.34 (0.89–2.01)

0.15

1.65 (1.04–2.61)

0.03

N/A

N/A

1.68 (1.08–2.62)

0.02h

  1. EFS Event-free survival; OS Overall survival; HR Hazard ratio; 95% CI 95% Confidence interval; SNV Single nucleotide variant; N/A Not applicable. Component 3: encompasses high levels of NK cells (CD57+), low levels of IL17A and low Ki-67. Component 4: encompasses high Ki-67 index and high counts of CD68+ and CD163+ macrophages. (*) Adjustement for B-symptoms and the MIPI index (EFS); adjustement for B-symptoms and bone marrow infiltration (OS).ap (bootstrap) = 0.02, bp (bootstrap) = 0.12, cp (bootstrap) = 0.004, dp (bootstrap) = 0.12, ep (bootstrap) = 0.004, fp (bootstrap) = 0.03, gp (bootstrap) = 0.11, hp (bootstrap) = 0.04
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us